- Details
- Christos Kyriakopoulos discusses the phase 1/2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer. Dr. Kyriakopoulos discusses the trial design, focusing on the completed phase 1 results and ongoing phase 2 study. The phase 1 data show the combination is well-tolerated with promising efficacy, including an 88% PSA-90 response rate in evaluable patients. The t...
|
- Details
- Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Mehra discusses the trial's design, which focuses on four subgroups: mismatch repair deficiency, high tumor mutational burden, CDK12 inactivation, and BRCA2 m...
|
- Details
- Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...
|
- Details
- Oliver Sartor host Dana Rathkopf for a discussion on BMS-986365, a novel androgen receptor ligand-directed degrader for prostate cancer treatment. Dr. Rathkopf discusses the drug's unique dual mechanism of action, which both degrades and competitively inhibits the androgen receptor. She presents data from the phase I/II trial, highlighting the drug's efficacy, particularly in patients without prio...
|
- Details
- Neeraj Agarwal discusses a post-hoc analysis of the TALAPRO-2 Phase III study, which evaluates the efficacy of talazoparib and enzalutamide in metastatic castrate-resistant prostate cancer patients with prior ARPI or docetaxel treatment. The analysis shows promising results for the combination therapy, particularly in patients with HRR-deficient tumors. Dr. Agarwal emphasizes the potential benefit...
|
- Details
- Oliver Sartor interviews Neeraj Agarwal about the CONTACT-02 trial, which compares cabozantinib plus atezolizumab to second ARPI in metastatic castrate-resistant prostate cancer patients. Dr. Agarwal presents the final overall survival results from the study, which shows improved progression-free survival with the combination therapy, particularly in patients with liver or bone metastasis. While o...
|
- Details
- Oliver Sartor interviews John Valliant about the potential of radiopharmaceuticals in cancer treatment. Dr. Valliant discusses the advantages of targeted radiation therapy, particularly using Actinium-225, highlighting its efficacy and potential for combination therapies. He emphasizes the unique ability of radiopharmaceuticals to combine imaging and treatment, allowing for better patient selectio...
|
- Details
- David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....
|
- Details
- Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...
|
- Details
- Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
|
